A double-blind randomized withdrawal study evaluating the efficacy and safety of SR58611A [amibegron] versus placebo in the prevention of relapse of anxiety up to 1 year in patients with GAD [generalised anxiety disorder] improved after 12 weeks of open label treatment with SR58611A

Trial Profile

A double-blind randomized withdrawal study evaluating the efficacy and safety of SR58611A [amibegron] versus placebo in the prevention of relapse of anxiety up to 1 year in patients with GAD [generalised anxiety disorder] improved after 12 weeks of open label treatment with SR58611A

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Amibegron (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Acronyms VEGA
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2009 Actual patient number (257) added as reported by ClinicalTrials.gov.
    • 25 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top